Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab by Retseck, J et al.
RESEARCH ARTICLE Open Access
Phenotypic and functional testing of
circulating regulatory T cells in advanced
melanoma patients treated with
neoadjuvant ipilimumab
Janet Retseck, Robert VanderWeele, Hui-Min Lin, Yan Lin, Lisa H. Butterfield and Ahmad A. Tarhini*
Abstract
Background: We have previously investigated neoadjuvant ipilimumab (ipi) for patients with locally/regionally
advanced melanoma. That initial assessment of peripheral blood mononuclear cells (PBMC) showed a significant
increase in shared tumor associated antigen specific CD4+ and CD8+ T cell activation. We also observed a transient
increase in circulating T regulatory cells (Treg) with a parallel increase in total CD4+ T cells, as well as a significant
decrease in circulating myeloid derived suppressor cells (MDSC). The increase in circulating Treg frequency, as
assessed at 6 weeks after initiation of ipilimumab, was significantly associated with improved progression free
survival (PFS, p = 0.034; HR = 0.57) and returned to baseline levels by 12 weeks. To shed light on the unexpected
positive correlation between increased Treg and PFS, we here investigated the suppressive activity of circulating
Treg at baseline and 6 weeks.
Methods: Patients were treated with ipi (10 mg/kg intravenously every 3 weeks for 2 doses) bracketing definitive
surgery. Treg (CD4+CD25+CD127dim/-) were isolated from pre-ipi (baseline) and post-ipi (6 weeks) PBMC samples.
Treg were co-cultured with autologous responder CD4+ T cells that were stimulated with OKT3/IL-2/CD28 and
CFSE-labeled T cells. 1:1, 1:2, and 1:5 ratios were tested. Flow cytometery was used to evaluate the degree of Treg
proliferation suppression.
Results: Thirty-five patients were enrolled in the study; 18 patients had adequate PBMC samples with sufficient
Treg isolated for Treg functional analysis. At 6 weeks following ipi, a decrease in percent of maximal inhibition of
Th by Treg compared to baseline was seen for some patients. Scatter plot analysis showed no association between
Treg frequency and function at any ratio or between circulating Treg frequency and function at baseline and at 6 weeks
post-ipi. An increase in Treg suppressive function was significantly associated with a decrease in PFS (p = 0.02).
Conclusions: We find that Treg frequency measures do not correlate with suppressive activity measured ex vivo. Treg
suppressive activity increases correlate with poorer patient outcomes.
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Background
Locally and regionally advanced melanoma has a high
recurrence and mortality rate, with a 5-year survival for
Stage IIIA, IIIB, and IIIC disease of 78 %, 59 %, and
40 %, respectively [1]. At the time of this study, the only
Food and Drug Administration (FDA)-approved post-
operative adjuvant treatment for high risk melanoma
(Stages IIB - III) following wide local excision and lymph
node dissection was interferon alpha-2b (IFN) or ipili-
mumab at 10 mg/kg. Approval of IFN was granted based
on the results of four clinical trials. In E1684, IFN was
dosed at 20 million units (MU)/m2/day intravenously for
1 month followed by 11 months of maintenance IFN at
10 MU/m2 SQ three times a week vs. observation alone.
At median follow up of 6.9 years (for n = 280), both
relapse-free survival (RFS) (HR 0.61; p = 0.0013) and
overall survival (OS) (HR 0.67; p = 0.0115) were signifi-
cantly better for IFN vs. observation [2]. High-dose
interferon was subsequently shown to have superior RFS
to low-dose interferon and to observation in E1690 [3]
and to have superior RFS and OS to the GM2 ganglio-
side vaccine GMK in E1694 [4]. Pegylated IFN has also
been shown to improve RFS as compared to placebo in
the EORTC 18071 trial [5]. IFN remained the only
FDA-approved adjuvant treatment for high-risk melan-
oma for many years. However, toxicities associated
with IFN can lead to frequent dose reductions or sig-
nificant shortening of the length of treatment [6]. The
toxicity attrition rate ranged from 26 % in E1684 to
10 % in E1694.
Ipilimumab (ipi) is a monoclonal antibody directed
against the immune checkpoint molecule CTLA-4,
which was approved by the FDA in 2011 at the dose of
3 mg/kg for use in patients with advanced inoperable
melanoma (inoperable Stages III and IV) [7]. Overall
survival can be durable; a pooled analysis of 1861 pa-
tients in clinical trials showed a median survival of
11.4 months (95 % CI 10.7–12.1 months). There was a
plateau in the survival curve at 3 years, with up to
10 years of follow up. The survival rate at 3 years was
22 % for both previously treated and treatment-naive pa-
tients who had received ipi [8]. More recently, adjuvant
ipi at 10 mg/kg was shown to improve RFS of patients
with stage III melanoma as compared to placebo in the
EORTC trial 18071 (HR 0.75, 95 % CI 0.64 – 0.90) [9].
Tumors evade the immune response by many mecha-
nisms, including the generation of an immune suppres-
sive environment both systemically and at the tumor
site. This is mediated in part by recruiting regulatory T
cells (Treg), which can recognize tumor-associated an-
tigens and expand, leading to suppression of anti-tumor
effector and helper T cells (Th). These cells can sup-
press in an antigen-specific and non-specific manner
and secrete suppressive soluble factors [10]. CTLA-4 is
a negative regulator of T cell activation and proliferation
[11]. In down-regulating the immune response, it keeps
autoimmunity in check [12]. CTLA-4 expression is up-
regulated on activated T cells, whereas CTLA-4 is
constitutively expressed on CD4+CD25+ Treg [13].
CTLA-4 expressed by CD4+CD25hiFoxp3+ Treg is
thought to contribute to suppression of T effector cells
(Teff ) and Th, as CTLA-4 deficiency has been shown
to decrease both self-tolerance and suppressive func-
tion of CD4+CD25+ Treg in tumor immunity [14]. It
has been shown that CTLA-4 blockade of Teff in-
creased Th function, while CTLA-4 blockade of Treg
decreased Treg suppressive function, and that both are
necessary for the anti-tumor activity of therapeutic
CTLA-4 antibodies [15]. If Treg function can be sup-
pressed through CTLA-4 blockade with an agent such
as ipi, then an immune response to tumor antigens can
potentially emerge and expand.
We have previously investigated neoadjuvant ipi for pa-
tients with locally and regionally advanced melanoma [16].
Patients underwent tumor biopsy prior to ipi and tumor
resection after 2 doses of ipi at 10 mg/kg IV three weeks
apart. Following ipi, there was a significant increase in
CD8+ tumor infiltrating lymphocytes (TIL) as determined
by immunohistochemistry (n = 24; p = 0.02). In a subset of
patients, TIL immune monitoring by flow cytometry was
also performed (n = 10). We observed increased tumor
infiltration following ipi by activated (CD69+) CD3+/CD4+
T cells (p = 0.06) and CD3+/CD8+ T cells (p = 0.2) com-
pared to baseline. There was also evidence of induction/
potentiation of memory T cells expressing cytokine (CD3
+/CD8+/CD45RO+/TNFα+; p = 0.03) but not naive (CD3+/
CD8+/CD45RO−/TNFα+; p = 0.44) T cells at 6 weeks.
There was a trend towards an inverse association between
the change in Treg in tumor and clinical benefit (complete
response/partial response/stable disease versus progressive
disease; p = 0.09). CD4+CD25hiFoxp3+ Treg infiltration
was higher at week 6 (mean change = 1.5; SD = 1.46) in the
progressive disease group, and lower in the clinical-benefit
group (mean change = −0.64; SD = 1.83).
Immune monitoring of the circulation was also per-
formed as part of the study. Assessment of peripheral blood
mononuclear cells (PBMC) showed a significant increase in
the percentage circulating Treg (CD4+CD25hiFoxp3+ and
CD4+CD25hiCD39+). Unexpectedly, a significant increase
in circulating Treg (CD4+CD25hi+Foxp3+) was associated
with improved outcome, while conversely, we observed a
significant decrease in circulating myeloid derived sup-
pressor cells (MDSC), also associated with improved
outcome. MDSC are known to inhibit T cell frequency
and activation. As expected with CTLA-4 blockade, the
increase in Treg paralleled an increase in the total CD4+
T cell population [17]. We speculated that Treg sup-
pressive function might be changed by ipi therapy,
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and that this might be discordant with the circulating
frequency. Therefore, in this study, we tested the sup-
pressive activity of circulating Treg.
Methods
Patients
The characteristics of the total patient population were
reported in the previously published study [16]. Character-
istics of the 18 tested here are shown in Table 1. Eligible
patients were 18 years or older and had clinically detect-
able locally and/or regionally advanced melanoma (cuta-
neous, mucosal or unknown primary).
Study design
Following excisional biopsy, patients received induc-
tion ipi at 10 mg/kg IV on Day 0 and Day 21, and
then underwent complete lymph node dissection. Pa-
tients received maintenance ipi at 10 mg/kg IV 2–4
weeks following lymphadenectomy, for a total of 2
doses 3 weeks apart. Blood was drawn into heparin
(for PBMC) tubes or tubes without anticoagulant (serum)
and processed by the Immunologic Monitoring Lab
upon receipt at baseline and at 6 weeks. PBMC were
isolated by Ficoll gradient and cryopreserved for
batched testing according to standard operating pro-
cedures (SOPs).
Treg isolation and testing
The Miltenyi Biotec Treg isolation (CD4+CD25+CD127dim/-)
kit was used to purify Treg according to manufacturer’s in-
structions. CD4+CD25− Th cells were similarly collected
and used as responder cells. These cells were labeled
with carboxyl fluorescent succinimidyl ester (CFSE),
and 96-well plates were coated with OKT3 and incu-
bated for 2 h. CFSE-labeled responder cells without
Treg were added to the negative control wells and were
used as background for “minimal” level of proliferation.
The remaining CFSE-labeled responder cells were stim-
ulated with CD28 and IL-2 and added to appropriate
wells. Positive controls were OKT3/CD28/IL-2 stimu-
lated Th without Treg addition and were set to 100 %
or “maximal” level of proliferation. The Treg were then
added to corresponding wells at the different ratios.
The plates were incubated for 5 days in 37 °C, 5 %
CO2. Following incubation, cells were stained with sur-
face markers CD4 R-Phycoerythrin (PE) PE-Cy5 and
CD25 PE/Cy7 fluorescent dyes for flow cytometry. Rep-
resentative control flow cytometry plots are shown in
Additional file 1: Figure S1. Healthy donor control pro-
liferation inhibition assays are shown in Additional file
2: Table S1, while Additional file 3: Table S2 provides
data on Treg purification by flow. To compare data
between patients, each blood sample was normalized to
0 % baseline proliferation and 100 % proliferation with-
out Treg (maximum), with each Treg ratio falling in
between (Table 2).
Daily FC500-flow cytometer QC was run using
Beckman-Coulter Flow-Check, Flow-Check675 and
Flow-Check770 for laser alignment verification.
Beckman-Coulter Flow-Set fluorospheres were used to
standardize voltages to ensure consistency from day-
to-day. Single-stained Beckman-Coulter Immuno-Trol
control cells were used to establish compensation
settings. Beckman-Coulter CXP Software version 2.1
and Beckman-Coulter Kaluza Software version 1.2
were used.
Statistical analysis
Spearman correlation coefficients were used to evalu-
ate the correlation between change of Treg function
(6 weeks-baseline) and the Treg frequency previously
measured, as well as correlation between circulating
Treg frequency and function at baseline and 6 weeks.
We determined the direction of Treg function change
at 6 weeks by comparing to baseline by the majority
vote of the three ratios. Kaplan-Meier method was
used to evaluate progression free survival (PFS), and
the exact log rank test was used to compare the PFS
between the patients whose Treg function decreased
at 6 week after the treatment and those whose Treg
function increased at 6 weeks.
Table 1 Patient demographics and baseline disease characteristics
(N = 18 patients)
Variable No. of patients (%)
Age, years; median (range) 53 (30–73)
Cutaneous primary 17 (94)
Unknown primary 1 (6)
Gender
Female 12 (67)
Male 6 (33)
Performance status (ECOG)a
0 11 (61)
1 7 (39)
Recurrent disease after prior surgery 15 (83)
Prior adjuvant HDIb 6 (33)
Presence of in-transit metastases 12 (67)
Estimated risk stage
IIIB 2 (11)
IIIC 16 (89)
Tumor mutational status
BRAFV600 9 (50)
NRASQ61 5 (28)
Unknown 1 (5)
aECOG: Eastern Cooperative Oncology Group; bHDI: high dose interferon-α
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Results
Thirty-five patients were enrolled in the study. We pre-
viously reported the circulating frequencies of Treg and
other cells in this study [16]. Eighteen patients had ad-
equate remaining PBMC samples with sufficient Treg
cells for functional analysis. CD4+CD25+CD127low cells
were purified and tested for proliferation inhibition
(suppressive) function against patient autologous CD4+
T cells, which were stimulated with anti-CD3, anti-
CD28, and IL-2. The percent of proliferation inhibition
across several titrated Treg:Th ratios is shown in
Table 2. Patients varied in the suppressive activity of
their Treg. The range of proliferation inhibition at 1:1
Treg:Th was 19–81 %. At six weeks’ post-ipi, a decrease
in the percent of maximal inhibition of Th by Treg
compared to baseline (at 2 or 3 of the 3 tested Treg
ratios) was seen for 11 of 18 patients (Table 2). When
ratios were statistically examined separately, the change
in Treg suppression after treatment was not significant
for the highest Treg ratios of 1:1 (p = 0.1439) or 1:2
(p = 0.782). It was significant only for the 1:5 ratio (p =
0.02557, Additional file 4: Figure S2).
To understand the relationship between the sup-
pressive function measured at the different Treg:Th
ratios and the circulating frequencies, we investigated
the association between them. We examined both
CD4+CD25hiFoxp3+ and CD4+CD25hiCD39+ Treg cells.
Foxp3 is an accepted marker of these cells; however,
there is evidence that CD39 may be a more reliable
marker of Treg [18]. CD4+CD25hiCD39+ T cells may
have more immunosuppressive function through pro-
duction of adenosine [19], and they have been found
in increased levels in cancer patients [20]. A central
finding of this study was that no statistically signifi-
cant association between the change of Treg fre-
quency after treatment and the Treg suppressive
function (change of Treg proliferation inhibition post
treatment) at any ratio was observed (Fig. 1). It was
possible that increases or decreases in suppression
after ipi might be mirrored in the circulating frequen-
cies. However, there was also no statistically signifi-
cant association between circulating Treg frequency
and function tested at baseline and 6 weeks post-ipi
(Fig. 2). The literature suggests that Treg mediated
immune suppression has a negative impact on tumor
control. Importantly, Treg suppressive function post-
treatment (which was defined by taking a majority of
three ratios, i.e. if the data from at least two of the
Table 2 Percent proliferation inhibition by Treg at different Treg:Th ratios at either baseline or 6 week timepoints
aTimepoint; bTreg:Th ratio; cPatient number; dResults highlighted in blue represent a decrease in percent of maximal inhibition post-ipi compared to corresponding
baseline sample
Retseck et al. Journal for ImmunoTherapy of Cancer  (2016) 4:38 Page 4 of 8
three ratios showed Treg suppression post-treatment)
was associated with a statistically significant decrease
in PFS six weeks after treatment with ipi (p = 0.02381,
Fig. 3). While an increase in Treg suppressive function
over time was associated with a significant decrease in
PFS, we did not see a correlation between the baseline
proliferation inhibition and PFS.
Discussion
We found that Treg suppression of autologous CD4+ T
cell proliferation was changed after ipi treatment in a
subset of patients, which did not mirror the circulating
Treg phenotypic analysis performed. There were no sig-
nificant overall trends across patients for ipi-induced
Treg functional changes. The function of Treg in healthy
individuals is to down-regulate the immune response
and establish peripheral tolerance, guarding against
autoimmunity. Treg suppress T cell function by several
different mechanisms and to varying degrees, including
suppression by secretion of inhibitory cytokines such as
IL-10 and TGFβ; destruction of tumor cells via
granzyme-A and perforin; metabolic disruption though
adenosine nucleosides; and perhaps through targeting of
dendritic cells [21]. It is thought that tumors manipulate
the tumor microenvironment (TME) to induce Treg
suppression of Th, and that different tumors may affect
both the TME and Treg differently [22]. Questions have
also been raised concerning whether Treg not only sup-
press the immune response under influence of tumor-
derived factors, but also work to dampen inflammatory
responses that would otherwise promote tumor growth,
as increased Treg infiltration of tumor and in the per-
ipheral blood has been associated with both poor and
good prognosis, depending on the tumor [23]. A review
of 124 studies of immune infiltration of the tumor itself
demonstrated that Treg were considered to have a
“good” effect on prognosis in a little over 30 % of studies
and a “poor” effect in just over 40 % of studies; the
Fig. 1 Association between the change in peripheral blood Treg frequency and Treg suppressive function (change in % Treg proliferation after
the treatment) across different Treg:Th ratios. The change (week 6 level – baseline level) in circulating Treg was measured phenotypically as
CD4+/CD25hi/Foxp3+ (Diff CD4+CD29hiFoxp3+, left column), CD4+/CD25hi/CD39 (Diff CD4+CD25+CD39+, middle column), or the percent of
circulating Treg (Diff %Treg in CD4+ Cells, right column). The percent suppressive activity, calculated as the week 6 % Treg inhibition – baseline % Treg
function, at 1:1 (Diff 1:1, top row), 1:2 (Diff 1:2, middle row), or 1:5 (Diff 1:5, bottom row) was plotted against the frequency of Treg across all patients
with valid test results. There was no statistically significant association (p values on each part). Fewer than 18 data points were generated
due to missing values on some patients
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remainder found no effect [24]. Part of the difficulty in
determining the role of Treg in tumor immune response
is the difficulty in identifying Treg in vivo. The precise
phenotypic identification of Treg remains under discus-
sion; however, there is recent consensus that identifica-
tion can be made by establishing suppressive activity
[25]. It is therefore possible that phenotypic measures of
circulating Treg do not necessarily mirror functional
changes. A limitation to this study is that there was
not sufficient material from the tumor to compare the
suppressive function of Treg in both peripheral blood
and tumor. Likewise, we were not able to measure sup-
pressive cytokines IL-10 and TGF-beta in the Treg
suppression assay cultures.
Our finding that the post-ipi isolated Treg exhibited
proliferation inhibition activity in vitro shows that they
maintained their suppressive function. Treg suppressive
activity did not significantly change before and after ipi
at the highest tested ratios. This is in accord with previ-
ous studies, which have shown an increase in functional
Treg in concert with a much greater increase in active
Th following administration of an anti-CTLA-4 anti-
body, leading to the observed anti-tumor effect [26, 27].
In contrast, a separate study found that Th developed
resistance to Treg inhibition after one month of treat-
ment [28]. Another study similarly found that in vitro, at
least, CTLA-4 blockade with tremelimumab negated the
suppression of Th by Treg, more so at higher Th to Treg
ratios. This may correlate with our finding of a signifi-
cant decrease in Treg suppression of Th at 1:5 dilution.
Fig. 2 Association between circulating Treg frequency and Treg function (% Treg function, pre- and post-treatment). Baseline phenotypic
(baseline circulating Treg cells) and suppressive function at each ratio (baseline %Treg function; top row), and post treatment measures
(bottom row) were tested across patients for correlations. There was no significant association (p values on each part). Fewer than 18 data points were
generated due to missing values on some patients
Fig. 3 Association between reduced progression free survival with
increase in circulating Treg. The patients were divided into two groups:
those with % inhibition increased and those with % inhibition
decreased. We defined the group by taking a majority of the
three ratios. That is, if the results of at least 2 of the 3 ratios
indicated a higher % inhibition at week 6 than at baseline, the
patient was included in the WK6 > BL group, and if the results of
at least 2 of the 3 ratios indicated a lower % inhibition at week
6 than at baseline, then the patient was included in the WK6 < BL group.
Suppressive activity over time is shown in a Kaplan-Meier plot. Increase
in Treg suppressive function was significantly associated with a decrease
in PFS (p= 0.02381)
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The study concluded that the effect of CTLA-4 was not
due to an effect on Treg, but to activation of Th [29].
We previously also observed elevated numbers of Th
and Treg following treatment with tremelimumab. We
hypothesized that CTLA-4 blockade acts on Th to in-
hibit CTLA-4 suppression and allow greater expansion,
leading to an antitumor response [30]. The association
of an increase in circulating CD4+CD25hiFoxp3+ Treg at
6 weeks following CTLA-4 blockade with an increase in
PFS may relate more to a concomitant and greater in-
crease in the overall T cell population, of which Treg are
a small fraction, than in the functionality of Treg. The
impact of ipi on Th may outweigh its effect on Treg.
Therapeutic effects may depend on optimal CD8+ ef-
fector to Treg ratios [28]. We previously reported the
detection of type I (interferon-γ producing), fully acti-
vated (CD69+) CD4+ and CD8+ antigen-specific T-cells
(specific to gp-100, MART-1 and NY-ESO-1) that were
significantly potentiated by ipilimumab [16]. Significant
increases (3–10 fold) in CD3+/CD4+/INF-γ+ T-cells were
observed only in patients who were progression free at
6-months. Moreover, Treg in tumor tended to be de-
creased post-ipi in responders. Therefore, what we see in
the circulation may not be reflective of what happens in
the TME. By testing Treg suppressive function, we ob-
served trends of increase or decrease in suppressive
function after ipi in individual patients that did not
reach statistical significance over the entire group of pa-
tients. In this study, CD8+ cells were eliminated as part
of the isolation process, and therefore we were unable to
determine if they are less resistant to suppression than
CD4+CD25− cells. Another limitation to the study is that
numbers are small.
Another limitation of the study is that we were unable to
test CD4+CD25+Foxp3+ cells directly for functionality. A
recent consensus statement by The Association for Cancer
Immunotherapy (CIMT) immunoguiding program (CIP)
concluded that minimally required markers of human Treg
are CD3, CD4, CD25, CD127, and Foxp3 [31]. However,
intracellular labeling of Foxp3 involves fixing the cells, thus
making them unsuitable for further functional assays. In-
stead, we isolated a population of CD4+CD25+CD127dim
regulatory T-cells. CD127dim is a marker for suppressor T
cells. Using this method therefore may have selected for
functional suppressor Treg rather than the entire popula-
tion of CD4+CD25+Foxp3+ Treg. Another limitation is that
in the phenotypic analysis, we did not surface stain for
CTLA-4 expression.
Conclusions
We found that Treg frequency measures do not correlate
with suppressive activity measured ex vivo. However, Treg
suppressive activity increases do correlate with poorer
patient outcomes.
Additional files
Additional file 1: Figure S1. Changes in Treg suppression of Th at 6
weeks compared to baseline. The bar graph on the left shows 1:1 Treg:Th
ratio; the change was not significant (p = 0.1439). The middle bar graph
shows 1:2 Treg:Th; the change was not significant (p = 0.782). The right
bar graph shows 1:5 Treg:Th; the change was significant (p = 0.02557).
(DOCX 3760 kb)
Additional file 2: Table S1. Healthy donor control proliferation inhibition
assays. (DOC 30 kb)
Additional file 3: Table S2. Treg purification flow cytometry profile.
(DOC 117 kb)
Additional file 4: Figure S2. Representative flow cytometry plots. The
top row shows flow cytometry results for Treg (CD25+CD127dim/neg) and
Responders (CD4+CD25-CD127dim/neg). The middle row shows Negative
Control and Positive Control flow cytometry plots. The bottom row shows
an example suppression control for Treg:Responders at 1:1, 1:2, and
1:5 dilutions. (DOCX 342 kb)
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